BioSpace News Archive

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced that data from the Company’s bridging study in healthy volunteers of a solid formulation of SYNB1618 support its continued development for the treatment of phenylketonuria (PKU).

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced the formation of the GeoMx™ Breast Cancer Consortium (GBCC).

Amylgen and Neuron-Experts, two leading preclinical CROs specialized in CNS pathologies, today announced an exclusive and strategic partnership that combines their respective in-vivo and in-vitro expertise to provide a new offering for a rapid efficacy assessment of compounds in neurodegenerative diseases.

The Oncopole, the MEDTEQ Consortium, the TransMedTech Institute and the Cancer Research Society, as part of the joint Onco-Tech Competition, are proud to announce a $2.6M investment to support innovative projects in oncology and in medical technologies.

Ambetter from Buckeye Health Plan’s new online enrollment platform gives new and renewing consumers a one-stop shop for getting healthcare coverage

The Michael D. Ratner Center for Early Detection of Cancer Launches Mobile Low-Dose CT Unit to Screen for Lung Cancer

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced positive, initial ex-vivo results of PTI’s proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808, and PTI-428,

EVO/EVO+ VISIAN® Implantable Collamer® Lens for Myopia, and EVO/EVO+ VISIAN® Toric Implantable Collamer® Lens for Myopia with Astigmatism

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The University of Texas MD Anderson Cancer Center exercised its option to license Bellicum’s CaspaCIDe® safety switch technology.

Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill® (AP) for a proprietary Novartis compound, despite the AP having met the technical and pharmacokinetic (PK) clinical specifications set forth by Novartis